Is docetaxel (Taxotere®) or vinorelbine (Navelbine®) better for the treatment of early breast cancer?
Study: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatment of breast cancer: Final reports of the FinHer trial. Study Design: A randomized, controlled, open-label phase III trial Study Eligibility: Women aged 65 years or younger who had undergone mastectomy or breast conserving surgery with axillary nodal dissection for invasive breast cancer. Enrollment: 1,010 women The FinHer (Finland Herceptin®) trial was an open, phase III trial that looked at 1,010 women with node-positive or high-risk node-negative breast cancer. Two hundred thirty-two women with Her2-positive breast cancer were assigned to receive trastuzumab (Herceptin®) for 9 weeks with docetaxel (Taxotere®) or vinorelbine (Navelbine®) or only docetaxel or vinorelbine. The primary endpoint of the trial was distant-disease-free survival (DDFS), defined as the time period from the date of randomization to the date of first cancer recurrence other
Related Questions
- How can I learn more about breast cancer risk factors and ways to find breast cancer early, when treatment works best?
- Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
- Are there any techniques under way to improve early breast cancer detection and treatment?
